NervGen Q2 2026 loss reflects continued spending on NVG-291, NVG-300 development, company says

• NervGen’s commentary for the three and six months ended June 30, 2026 centered on continued spending tied to development of NVG-291.
• Management highlighted preparations to initiate a Phase 3 trial in chronic tetraplegia as the key operational driver.
• Development pace remained influenced by an FDA partial clinical hold on NVG-291 for spinal cord injury.
• The company framed near-term performance around funding needs, cash use, and the timing of clinical milestones.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief on August 13, 2026, and is solely responsible for the information contained therein.